(0.07%) 5 473.33 points
(0.10%) 39 150 points
(0.38%) 17 785 points
(0.16%) $80.96
(-3.66%) $2.66
(-0.77%) $2 312.90
(0.25%) $28.94
(3.64%) $1 022.30
(0.29%) $0.936
(0.67%) $10.68
(0.44%) $0.792
(-0.28%) $87.24
Live Chart Being Loaded With Signals
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation...
Stats | |
---|---|
今日成交量 | 1 000 |
平均成交量 | 0 |
市值 | 192 605 |
EPS | $-0.290 ( Q2 | 2023-08-18 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-27 | Lamond Stephen J | Buy | 2 600 | Common Stock |
2023-09-26 | Lamond Stephen J | Buy | 3 000 | Common Stock |
2023-09-18 | Lamond Stephen J | Buy | 2 500 | Common Stock |
2023-09-15 | Lamond Stephen J | Buy | 11 750 | Common Stock |
2023-09-21 | Huh Hoyoung | Buy | 45 000 | Common Stock |
INSIDER POWER |
---|
36.66 |
Last 35 transactions |
Buy: 4 014 898 | Sell: 1 708 333 |
Peak Bio, Inc. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Peak Bio, Inc. 财务报表
Annual | 2022 |
营收: | $607 681 |
毛利润: | $607 572 (99.98 %) |
EPS: | $-0.740 |
FY | 2022 |
营收: | $607 681 |
毛利润: | $607 572 (99.98 %) |
EPS: | $-0.740 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Peak Bio, Inc.
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company\'s proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。